Review of Nexavar data presented at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO)

June 1 - 5, 2007
Chicago, Illinois

Results from various clinical studies including a pivotal Phase III trial in patients with advanced hepatocellular carcinoma, or primary liver cancer with Nexavar® (sorafenib) tablets were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).

Monday, June 4, 2007 at 2:00 p.m. CEST:
Investor Conference Call - Review of Nexavar Data presented at ASCO

MP3 audio recording (presentation and discussion)

Fact Sheets
Nexavar Fact Sheet
Download (PDF, 87 KB) collect
Renal Cell Carcinoma Fact Sheet
Download (PDF, 52 KB) collect
Hepatocellular Carcinoma Fact Sheet
Download (PDF, 62 KB) collect
Melanoma Fact Sheet
Download (PDF, 55 KB) collect
Non-Small Cell Lung Cancer Fact Sheet
Download (PDF, 54 KB) collect

Abstract on Nexavar (Sorafenib) at ASCO 2007

Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial) - abstract LBA1

Clinical trials information:

American Cancer Society:

American National Cancer Institute:

Information on kidney cancer:

Information on liver cancer:

Information on melanoma:

Information on lung cancer:

Information on cancer incidence, prevalence and mortality (GLOBOCAN):

Last updated: January 09, 2014 Copyright © Bayer AG